ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake

Rhea-AI Filing Summary

ARCH Venture-affiliated funds filed Amendment No. 4 to a Schedule 13D reporting their beneficial ownership in Neumora Therapeutics, Inc. The ARCH funds report beneficial ownership of 33,847,838 shares of Common Stock, representing 18.6% of Neumora’s outstanding shares, based on 182,040,945 shares reported outstanding in the issuer’s recent annual report.

Individual reporting persons include Kristina Burow with 33,965,419 shares deemed beneficially owned (18.7%), reflecting fund interests plus personal holdings, options and restricted stock units, and Steven Gillis with 31,526,272 shares (17.3%). The group states that no reporting person has effected transactions in Neumora’s stock during the last 60 days.

Insights

Equity ownership & governance analyst

ARCH funds reaffirm a large, stable Neumora stake with no recent trading activity.

The filing shows ARCH Venture funds and related entities collectively reporting beneficial ownership around 18.6%–18.7% of Neumora Therapeutics common stock. This is characterized mainly through fund record holdings where various ARCH partnerships and LLCs act as general partners with shared voting and dispositive power.

The filing clarifies detailed record ownership across AVF VII, AVF VIII Overage, AVF X, AVF X Overage and AVF XII, and explains how individuals like Kristina Burow and Steven Gillis have pecuniary interests and additional personal equity and options. It also states that none of the reporting persons has traded Neumora shares in the last 60 days, suggesting the amendment primarily updates ownership disclosure rather than signaling new buying or selling.

Key Figures

ARCH funds beneficial ownership: 33,847,838 shares (18.6%) Shares outstanding: 182,040,945 shares Kristina Burow beneficial ownership: 33,965,419 shares (18.7%) +5 more

8 metrics

ARCH funds beneficial ownership 33,847,838 shares (18.6%) Neumora common stock beneficially owned by each main ARCH reporting person

Shares outstanding 182,040,945 shares Neumora common stock outstanding as reported in Form 10-K used for ownership calculations

Kristina Burow beneficial ownership 33,965,419 shares (18.7%) Includes fund interests, personal shares, options and restricted stock units

Steven Gillis beneficial ownership 31,526,272 shares (17.3%) Neumora common stock deemed beneficially owned by Steven Gillis

AVF VII record shares 1,387,228 shares Common stock held of record by ARCH Venture Fund VII, L.P.

AVF X record shares 12,205,379 shares Common stock held of record by ARCH Venture Fund X, L.P.

AVF X Overage record shares 11,886,758 shares Common stock held of record by ARCH Venture Fund X Overage, L.P.

AVF XII record shares 6,046,907 shares Common stock held of record by ARCH Venture Fund XII, L.P.

Key Terms

Schedule 13D, beneficial ownership, pecuniary interest, restricted stock units, +2 more

6 terms

Schedule 13D regulatory

"This Amendment No. 4 amends the filed on September 29, 2023 (as amended, the "Original 13D")"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficial ownership financial

"Each Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"Burow and Gillis have a pecuniary interest in AVP VII, and Burow has a pecuniary interest in AVP VIII LP"

restricted stock units financial

"and 20,100 fully vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

general partner financial

"AVP VII, as the sole general partner of AVF VII, may be deemed to beneficially own the AVF VII Record Shares"

A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.

dispositive power financial

"shared power to dispose or to direct the disposition: See line 10 of cover sheets"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What ownership stake in Neumora Therapeutics (NMRA) do ARCH Venture funds report?

ARCH Venture funds report beneficial ownership of 33,847,838 shares of Neumora common stock. This represents about 18.6% of the company’s outstanding shares, based on 182,040,945 shares reported outstanding in Neumora’s recent annual report.

Which Neumora (NMRA) investors are named in this Schedule 13D/A amendment?

The amendment lists multiple ARCH entities and individuals, including ARCH Venture Fund VII, VIII Overage, X, X Overage and XII, affiliated ARCH Venture Partners entities, and individuals Robert Nelsen, Keith Crandell, Clinton Bybee, Kristina Burow and Steven Gillis as reporting persons.

How much Neumora (NMRA) stock is attributed to Kristina Burow and Steven Gillis?

Kristina Burow is reported to beneficially own 33,965,419 shares, or about 18.7% of Neumora, including fund interests, personal shares, options and restricted stock units. Steven Gillis is reported to beneficially own 31,526,272 shares, representing approximately 17.3% of the company’s common stock.

Did ARCH Venture or its principals trade Neumora (NMRA) shares recently?

The filing states that none of the reporting persons effected any transactions in Neumora common stock during the last 60 days. This suggests the amendment primarily updates and clarifies beneficial ownership positions rather than disclosing new purchase or sale activity.

What share count did ARCH use to calculate its Neumora (NMRA) ownership percentages?

Ownership percentages are calculated using 182,040,945 shares of Neumora common stock outstanding, as reported in the company’s Annual Report on Form 10-K filed on March 30, 2026. For Kristina Burow, certain option holdings are included in the outstanding share figure.

What is the purpose of this Neumora (NMRA) Schedule 13D/A Amendment No. 4?

Amendment No. 4 updates beneficial ownership information originally reported on Schedule 13D for Neumora Therapeutics. It details current record holdings across several ARCH funds and clarifies how affiliated general partners and individuals may be deemed to share voting and dispositive power over these shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Neumora Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

640979100

(CUSIP Number)

Mark McDonnell
ARCH Venture Management, LLC, 8755 W. Higgins Road, Suite 1025
Chicago, IL, 60631
(773) 380 6600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/30/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Fund VII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Fund VIII Overage, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Fund X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Fund X Overage, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Fund XII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners VII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners X Overage, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners XII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners VII, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners VIII, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners X, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

ARCH Venture Partners XII, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

Robert Nelsen

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

Keith Crandell

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,847,838.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.6 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

Clinton Bybee

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,708,794.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,708,794.00

11

Aggregate amount beneficially owned by each reporting person

3,708,794.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

Kristina Burow

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 117,581.00
8	Shared Voting Power 33,847,838.00
9	Sole Dispositive Power 117,581.00
10	Shared Dispositive Power 33,847,838.00

11

Aggregate amount beneficially owned by each reporting person

33,965,419.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 640979100

1

Name of reporting person

Steven Gillis

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 31,526,272.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 31,526,272.00

11

Aggregate amount beneficially owned by each reporting person

31,526,272.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

17.3 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value
(b)	Name of Issuer: Neumora Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 260 Arsenal Place, Suite 1, Watertown , MASSACHUSETTS , 02472.
Item 1 Comment: This Amendment No. 4 (the "Amendment No. 4") amends the Schedule 13D filed on September 29, 2023 (as amended, the "Original 13D"), related to the Common Stock, $0.0001 par value per share (the "Common Stock"), of Neumora Therapeutics, Inc. (the "Issuer") having its principal executive office at 260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472. Certain terms used but not defined in this Amendment No. 4 have the meanings assigned thereto in the Original 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 of the Original 13D is hereby amended and supplemented as follows: AVF VII is the record owner of 1,387,228 shares of Common Stock ("AVF VII Record Shares"). AVP VII, as the sole general partner of AVF VII, may be deemed to beneficially own the AVF VII Record Shares. AVP VII LLC, as the sole general partner of AVP VII, may be deemed to beneficially own the AVF VII Record Shares. AVF VIII Overage is the record owner of 2,321,566 shares of Common Stock ("AVF VIII Overage Record Shares"). AVP VIII LLC, as the sole general partner of AVF VIII Overage, may be deemed to beneficially own the AVF VIII Overage Record Shares. AVF X is the record owner of 12,205,379 shares of Common Stock ("AVF X Record Shares"). AVP X LP, as the sole general partner of AVF X LP, may be deemed to beneficially own the AVF X Record Shares. AVP X LLC, as the sole general partner of AVP X LP, may be deemed to beneficially own the AVF X Record Shares. AVF X Overage is the record holder of 11,886,758 shares of Common Stock ("AVF X Overage Record Shares"). AVP X Overage LP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Record Shares. AVP X LLC, as the sole general partner of AVP X Overage LP, may be deemed to beneficially own the AVF X Overage Record Shares. AVF XII is the record holder of 6,046,907 shares of Common Stock ("AVF XII Record Shares"). AVP XII LP, as the sole general partner of AVF XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVP XII LLC, as the sole general partner of AVP XII LP, may be deemed to beneficially own the AVF XII Overage Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each of the Managing Directors and direct and indirect general partners of AVF VII and AVF VIII Overage may be deemed to share the power to direct the disposition and vote of the AVF VII Record Shares and AVF VIII Overage Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and investment committee members, each of the Investment Committee Members and direct and indirect general partners of AVF X, AVF X Overage and AVF XII may be deemed to share the power to direct AVF X Record Shares and AVF XII Record Shares (collectively with AVF VII Record Shares and AVF VIII Overage Record Shares, the "Record Shares"). Burow and Gillis have a pecuniary interest in AVP VII, and Burow has a pecuniary interest in AVP VIII LP and AVP VIII Overage LP, and while they do not have voting or dispositive power over AVF VII Record Shares or AVF VIII Record Shares, these shares were included in the beneficial ownership reporting for each. Burow is also the owner of 27,617 shares of common stock of the Issuer and is the holder of vested options to purchase 67,283 shares of Common Stock and options to purchase 2,581 shares of Common Stock that will vest within 60 days of this Schedule 13D ("Burow Options"), and 20,100 fully vested restricted stock units. Each Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage (other than for Burow) was calculated based on 182,040,945 shares of Common Stock outstanding, as reported by the Issuer in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2026. For Burow, the Burow Options were included in the number of shares of Common Stock outstanding.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	None of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund VII, L.P.

Signature:	ARCH Venture Partners VII, L.P.
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	ARCH Venture Partners VII, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

ARCH Venture Fund VIII Overage, L.P.

Signature:	ARCH Venture Partners VIII, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

ARCH Venture Fund X, L.P.

Signature:	ARCH Venture Partners X, L.P.
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:	04/01/2026

ARCH Venture Fund X Overage, L.P.

Signature:	ARCH Venture Partners X Overage, L.P.
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:	04/01/2026

ARCH Venture Fund XII, L.P.

Signature:	ARCH Venture Partners XII, L.P.
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	ARCH Venture Partners XII, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

ARCH Venture Partners VII, L.P.

Signature:	ARCH Venture Partners VII, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

ARCH Venture Partners X, L.P.

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:	04/01/2026

ARCH Venture Partners X Overage, L.P.

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:	04/01/2026

ARCH Venture Partners XII, L.P.

Signature:	ARCH Venture Partners XII, LLC
Name/Title:	its General Partner
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

ARCH Venture Partners VII, LLC

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Date:	04/01/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
Date:	04/01/2026

ARCH Venture Partners VIII, LLC

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

ARCH Venture Partners X, LLC

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:	04/01/2026

ARCH Venture Partners XII, LLC

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	04/01/2026

Robert Nelsen

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
Date:	04/01/2026

Keith Crandell

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Date:	04/01/2026

Clinton Bybee

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
Date:	04/01/2026

Kristina Burow

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Kristina Burow
Date:	04/01/2026

Steven Gillis

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Steven Gillis
Date:	04/01/2026

Comments accompanying signature:

*This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.2 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.